On January 29, 2026, Secretary of Health and Human Services Robert F. Kennedy Jr. appointed Michelle Branham as the new chair of the Federal Alzheimer’s Advisory Council, along with ten additional public members. Branham, who serves as Secretary of the Florida Department of Elder Affairs, brings over 25 years of experience in Alzheimer’s disease policy and public health to the leadership role.
This represents a significant development for the nation’s primary advisory body on dementia policy, tasking the council with renewed focus on reducing the burden of Alzheimer’s disease and related dementias across the country. The article explores who was appointed, what qualifications they bring, and why these appointments matter for families and individuals affected by dementia. The new council composition reflects a shift toward representation from states actively engaged in aging services and dementia care infrastructure. Katheryn Newkirk was appointed as Vice Chair, and the ten new members bring expertise spanning senior leadership, public health, dementia advocacy, and patient perspectives—including individuals living with dementia themselves. These appointments signal an effort to ground federal policy advice in practical experience from the front lines of dementia care.
Table of Contents
- Who Were the New Members Appointed to the Federal Alzheimer’s Advisory Council?
- Understanding the Federal Alzheimer’s Advisory Council’s Role and Purpose
- Michelle Branham’s Background and Why Her Experience Matters
- What Expertise Do the New Members Bring to the Council?
- How the Council’s Structure Shapes What Recommendations Actually Reach Policy
- Historical Context—Why This Appointment Matters Now
- What These Appointments Mean for Dementia Policy and Families
- Conclusion
Who Were the New Members Appointed to the Federal Alzheimer’s Advisory Council?
The ten new public members appointed in January 2026 represent diverse professional backgrounds in aging, health, and dementia services. Among them is John Couris, CEO of the Florida Health Sciences Center, who brings corporate healthcare leadership perspective to the council. James Hartsell, Executive Director of the Florida Department of Veterans’ Affairs, adds experience managing health services for a particularly vulnerable population—veterans face higher rates of cognitive decline and dementia-related conditions.
Steve Waterhouse, Chair of the Alzheimer’s Association of Central and North Florida, represents the nonprofit advocacy sector that directly interfaces with families navigating diagnosis and care decisions. The collective qualifications create a mix of administrative expertise, clinical knowledge, and grassroots advocacy. However, it’s worth noting that many appointments skew toward Florida-based professionals, which means the council’s understanding of regional variations in dementia care systems, healthcare infrastructure, and resource availability may be weighted toward Southeast conditions. This geographic concentration could influence policy recommendations in ways that reflect Florida’s particular aging population—one of the oldest and most dementia-affected in the nation—rather than the full diversity of dementia challenges across different regions.
Understanding the Federal Alzheimer’s Advisory Council’s Role and Purpose
The Federal Alzheimer’s Advisory Council was established in 2011 under the National Alzheimer’s Project Act (NAPA), a bipartisan effort to create a coordinated national response to Alzheimer’s disease. The council’s formal role is to advise the Secretary of Health and Human Services on policies, programs, and initiatives aimed at reducing the burden of Alzheimer’s disease and related dementias—a category that includes vascular dementia, Lewy body dementia, frontotemporal dementia, and other cognitive decline conditions. The council meets quarterly to review federal efforts, identify gaps in research and services, and recommend priorities for funding and policy changes.
The council operates at a unique intersection: it must balance input from researchers seeking funding, clinicians reporting on patient needs, advocates demanding action, and government officials managing budgets and timelines. This creates inherent tension, because what researchers identify as most promising often differs from what patients most urgently need. For example, basic research into disease mechanisms may take years to yield treatments, while patients today need better memory care infrastructure and caregiver support. The council’s recommendations must navigate this gap, and new members with diverse backgrounds are meant to prevent any single perspective from dominating those recommendations.
Michelle Branham’s Background and Why Her Experience Matters
Michelle Branham’s appointment as chair reflects a deliberate choice to lead with someone rooted in public policy rather than clinical medicine or research. Her 25-plus years in Alzheimer’s disease policy, public health administration, and public communications provide experience managing dementia at scale—not just treating individual patients, but building systems, training staff, and communicating with the public. As Florida’s Secretary of Elder Affairs, she oversees state programs serving millions of older adults, many with cognitive impairment.
This is the operational experience that shapes how federal recommendations actually translate into funded programs and state-level action. However, policy-focused leadership can sometimes emphasize feasibility and budget constraints over bold innovation or increased investment. Branham’s background in Florida state government means she understands political and financial realities of expanding services, which is valuable context for federal advisors. But it also means the council will likely hear counsel rooted in “what Florida can manage and afford” rather than “what dementia patients would ideally need regardless of cost.” Her expertise in public communications is relevant too—dementia is historically underfunded relative to its disease burden, partly because public awareness lags, and her voice in national conversations may help reshape that perception.
What Expertise Do the New Members Bring to the Council?
Beyond the individual names and titles, the new members collectively represent several critical domains: senior leadership and organizational management (Couris); government administration of health services (Hartsell); and community-based advocacy (Waterhouse). This combination means the council can discuss federal policy proposals with people who understand how those policies land when implemented. For instance, if the council recommends expanding Medicare coverage for certain dementia diagnostics, Couris can speak to how hospitals would operationalize that; Hartsell can speak to how it would work within veteran healthcare systems; and Waterhouse can speak to what patients and families actually ask for when they call the Alzheimer’s Association.
The council also includes individuals living with dementia, whose presence shifts conversations from clinical abstraction to lived reality. However, if this representation is limited to one or two people, the council risks tokenizing patient voices—including them but not truly centering patient and caregiver needs in priority-setting. The specific number and diversity of patient-representatives appointed wasn’t fully detailed in the announcement, so the depth of patient voice in the council’s actual deliberations remains to be seen.
How the Council’s Structure Shapes What Recommendations Actually Reach Policy
The council meets quarterly, which means four times per year to discuss issues, review progress on federal initiatives, and draft recommendations that go to the HHS Secretary. Katheryn Newkirk’s appointment as Vice Chair provides structural continuity—if the chair needs to step back, the vice chair can maintain momentum and institutional memory. The quarterly schedule is both a strength and a limitation: frequent enough to stay current with emerging research and new needs, but infrequent enough that urgent issues can’t be addressed immediately. If a dementia-related public health crisis emerged, the council couldn’t convene an emergency session; it would have to wait for the next quarterly meeting or communicate through alternative channels. The council’s recommendations go to the HHS Secretary, who then decides which to act on, which to refer to other agencies, and which to shelve.
This means the council is advisory only—it has no budget authority, no regulatory power, and no guarantee that recommendations will be implemented. Strong council voices, combined with advocacy pressure and aligned research findings, can create momentum for change. But the actual impact depends entirely on whether the Secretary prioritizes those recommendations. In this case, that Secretary is Robert F. Kennedy Jr., an attorney and activist known for strong public health positions, which may mean he’s more likely to act on council advice than predecessors might have been—or conversely, that he may pursue his own agenda regardless of council input.
Historical Context—Why This Appointment Matters Now
The Federal Alzheimer’s Advisory Council has existed for fifteen years, but its profile and influence have varied depending on administration priorities. During periods when dementia policy was not a focal point, council recommendations could languish without action. The specific appointment of people with strong operational experience from Florida suggests an administration interested in translating federal advice into concrete state-level programs and infrastructure. Florida has particular relevance—it has among the oldest populations in America and therefore the highest absolute numbers of people with Alzheimer’s disease, making it a bellwether for national dementia care challenges.
Alzheimer’s disease burden continues to grow as the population ages. Currently, approximately 6.9 million Americans live with Alzheimer’s disease, with projections suggesting that number will increase significantly in coming decades. The disease costs the healthcare system roughly $290 billion annually, yet public funding for dementia research remains lower than for many other major diseases. This gap—between disease burden and research investment—is partly what the council exists to address. New leadership signaling commitment to dementia issues, with experienced operatives in the room, suggests the current administration may be taking this gap seriously.
What These Appointments Mean for Dementia Policy and Families
The appointment of Branham and the new council members signals a potential shift toward placing dementia services and caregiver support alongside research as federal priorities. This matters because federal policy influences what states fund, what research gets money, what insurance plans must cover, and ultimately what options are available to families. If the council recommends increased Medicare coverage for cognitive assessments, that affects accessibility. If it recommends federal investment in dementia care training for long-term care staff, that affects quality.
If it recommends support for caregiver respite programs, that affects whether families can avoid burnout and isolation. The council’s recommendations will be watched by researchers hoping for funding increases, patient advocates pushing for coverage expansion, and state officials trying to understand what federal priorities will shape their own budgets. Over the next two years, this council will likely address the evolving landscape of dementia treatment—including newer diagnostic approaches, potential disease-modifying therapies, and the pressing need for better infrastructure for people with early-stage dementia who aren’t yet ready for institutional care. Whether the council can bridge the gap between cutting-edge research and practical, affordable, accessible care at the community level will be a measure of whether these appointments translate ideals into outcomes.
Conclusion
The appointment of Michelle Branham as chair and ten new members to the Federal Alzheimer’s Advisory Council represents a renewal of the federal advisory structure charged with shaping America’s response to Alzheimer’s disease and related dementias. The council members bring diverse expertise—from healthcare administration and government service to community advocacy—that should deepen the council’s understanding of both what’s scientifically possible and what’s practically implementable. These appointments suggest an administration attentive to dementia policy, at least at the advisory level, though the ultimate impact depends on whether the HHS Secretary acts on the council’s recommendations and whether Congress provides funding for those recommendations.
For families affected by dementia, the council’s work matters in concrete ways: it influences which treatments insurance will cover, which services get federal research funding, and what standards states adopt for care facilities. Staying informed about the council’s quarterly recommendations and priorities is one way to understand where federal dementia policy is heading and where gaps still exist. Advocacy organizations and family associations often report on council activities, making it possible to track whether advice is actually being heeded and where continued pressure for change is needed.
